Novo Nordisk ($NVO) has had a big week. After announcing a $2 billion manufacturing investment Wednesday--and launching a late-stage trial of its oral semaglutide drug to boot--the Danish drugmaker now says it's buying two private biopharma research companies specializing in diabetes and related metabolic problems. Terms of the deals for its two buyout targets--Calibrium and MB2--weren't disclosed. Report